🔴 Ironwood Pharmaceuticals is trading 6.75% down today with no clear catalyst following recent FDA-related pressure

Ironwood Pharmaceuticals is trading at $3.73 (-6.75%) in pre-market sessions as no new company-specific news was identified to explain the move.

• The stock has faced ongoing pressure from FDA-required additional Phase 3 testing for apraglutide and subsequent analyst target cuts.
• The decline appears stock-specific, as broader market indices are only slightly lower and no new announcements were made on July 16.